COMMUNIQUÉS West-GlobeNewswire

Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models
22/01/2018
PLYMOUTH MEETING, Pa., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) today announced that Inovio’s synthetic vaccine approach using a collection of synthetic DNA antigens generated broad [...]
PetMed Express D/B/A 1-800-PetMeds Announces Its Third Quarter Financial Results and Increased Its Quarterly Dividend by 25% to $0.25 per Share
22/01/2018
Third Quarter New Order Sales Increased 15.5% Third Quarter Net Income Increased 88% Third Quarter Sales Increased 13.7% DELRAY BEACH, Fla., Jan. 22, 2018 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS ) today [...]
Sorrento Therapeutics to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference on 01/29/18
22/01/2018
SAN DIEGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) ("Sorrento"), announced today that it will present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference at [...]
Altimmune to Participate at the Noble Capital 14th Annual Investor Conference
22/01/2018
GAITHERSBURG, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT ), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a [...]
Encouraging Early Safety and Efficacy Data in Cynata’s Phase 1 Trial of CYP-001 in GvHD; DSMB Recommendation to Initiate Enrolment of Second Patient Cohort
22/01/2018
MELBOURNE, Australia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the independent Data Safety Monitoring [...]
PositiveID Corporation Announces Lawrence Livermore National Laboratory Evaluation of PositiveID’s FireflyDX
22/01/2018
DELRAY BEACH, Fla., Jan. 22, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (OTC:PSID), a life sciences company focused on detection and diagnostics, and its ExcitePCR Corporation subsidiary, announced today that [...]
Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer
22/01/2018
SAINT-GENIS-POUILLY, France, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ: AAAP ) (“AAA” or the “Company”), a leader in nuclear medicine theragnostics, today announced that a [...]
AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
22/01/2018
Mycobacterium Abscessus Load Reduced by 65% 6-Minute Walk Improvement Maintained at Day 81 NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused [...]
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
22/01/2018
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Metastatic Pancreatic Cancer Resistant to Gemcitabine who had Failed on Multiple Prior Treatments Rexahn is Progressing [...]
Athenex, Inc. Announces Proposed Offering of Common Stock
22/01/2018
BUFFALO, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer [...]
Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer
22/01/2018
SALT LAKE CITY, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, announced today that the company is applauding a new consensus [...]
Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference
22/01/2018
Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference Cambridge, Mass. - January 22, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global [...]
Athenex Announces Encouraging Early Clinical Efficacy and Safety Data of Oraxol in Clinical Trial for the Treatment of Breast Cancer
22/01/2018
BUFFALO, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer [...]
Endonovo Announces First Commercial Sales for SofPulse Wearable Electroceutical for Post-Operative Pain and Edema
22/01/2018
Seeking Distribution Partners in Europe for CE-Marked Electroceutical™ Device for Promotion of Wound Healing, Reduction of Pain and Post-Operative Edema LOS ANGELES, CA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Endonovo [...]
IRADIMED CORPORATION Announces 2018 Annual and First Quarter Financial Guidance
22/01/2018
Announces Preliminary Full Year and Fourth Quarter 2017 Revenue Announces Fourth Quarter 2017 Financial Results Conference Call Date WINTER SPRINGS, Fla., Jan. 22, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: [...]
Le conseil d’administration de la Société canadienne du sang a un nouveau président
22/01/2018
OTTAWA, 22 janv. 2018 (GLOBE NEWSWIRE) -- La Société canadienne du sang est heureuse d’annoncer la nomination de M. Mel Cappe à la présidence de son conseil d’administration. La nomination entre en vigueur immédiatement [...]
New board chair for Canadian Blood Services
22/01/2018
OTTAWA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Canadian Blood Services is pleased to announce the appointment of Mel Cappe as chair of the board of directors, effective immediately. With over 30 years of varied experience in [...]
Neuralstem to Participate at Cell and Gene Therapy World
22/01/2018
GERMANTOWN, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR ), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, Chief [...]
Athenex Announces Encouraging Results of the First Cohort of Phase I Clinical Trial of Oraxol and CYRAMZA® (Ramucirumab) Combination Treatment in Gastric Cancer
22/01/2018
BUFFALO, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

Pages